A pilot randomized trial of nebulized amphotericin in patients with allergic bronchopulmonary aspergillosis

• Published in: The Journal of asthma Vol. 53; no. 5; p. 517
• Main Authors: Ram, Babu, Aggarwal, Ashutosh N, Dhooria, Sahajal, Sehgal, Inderpaul Singh, Garg, Mandeep, Behera, Digambar, Chakrabarti, Arunaloke, Agarwal, Ritesh
• Format: Journal Article
• Language: English
• Published: England 01.06.2016
• Subjects: Adult; Amphotericin B - administration & dosage; Amphotericin B - therapeutic use; Antifungal Agents - administration & dosage; Antifungal Agents - therapeutic use; Aspergillosis, Allergic Bronchopulmonary - blood; Aspergillosis, Allergic Bronchopulmonary - drug therapy; Aspergillosis, Allergic Bronchopulmonary - physiopathology; Bronchodilator Agents - administration & dosage; Bronchodilator Agents - therapeutic use; Budesonide - administration & dosage; Budesonide - therapeutic use; Female; Forced Expiratory Volume; Humans; Immunoglobulin E - blood; Male; Nebulizers and Vaporizers; Pilot Projects; Vital Capacity; ABPM; Aspergillus; allergic mycosis; cystic fibrosis; allergy; asthma; ABPA

Nebulized amphotericin B (NAB) has been used in the management of acute stage and exacerbations of allergic bronchopulmonary aspergillosis (ABPA). Whether NAB can prevent exacerbations of ABPA is not known. Herein, we evaluate the efficacy and safety of NAB in subjects with ABPA complicating asthma....